Point72 Asset Management L.P. acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 88,146 shares of the company's stock, valued at approximately $1,840,000.
A number of other hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its stake in Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after purchasing an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC grew its holdings in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the period. Grandfield & Dodd LLC lifted its holdings in Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock valued at $704,000 after acquiring an additional 1,370 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after purchasing an additional 1,442 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.
Genmab A/S Price Performance
NASDAQ GMAB opened at $20.52 on Thursday. The firm has a market capitalization of $13.16 billion, a price-to-earnings ratio of 11.79, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. The company has a 50 day simple moving average of $19.75 and a 200-day simple moving average of $20.72. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $30.06.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. On average, analysts predict that Genmab A/S will post 1.45 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on GMAB. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Finally, William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $39.17.
Read Our Latest Stock Analysis on GMAB
About Genmab A/S
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
